Trials / Completed
CompletedNCT00953758
A Study Of PF-04449913 In Select Hematologic Malignancies
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS SINGLE AGENT IN SELECT HEMATOLOGIC MALIGNANCIES
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-04449913 | Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles |
Timeline
- Start date
- 2010-03-03
- Primary completion
- 2012-09-26
- Completion
- 2013-02-27
- First posted
- 2009-08-06
- Last updated
- 2024-04-25
- Results posted
- 2024-04-25
Locations
6 sites across 2 countries: United States, Italy
Source: ClinicalTrials.gov record NCT00953758. Inclusion in this directory is not an endorsement.